February 23, 2023
| Trial | Pola-R-ICE |
|---|---|
| Cancer Type | Lymphoma |
| Hospital(s) | Belfast City Hospital |
| Information | An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL) |
 |
Click Here to view Cancer Research UK trial summary |